WO1999032138A1 - Method for reducing susceptibility to hiv infection - Google Patents
Method for reducing susceptibility to hiv infection Download PDFInfo
- Publication number
- WO1999032138A1 WO1999032138A1 PCT/US1998/027005 US9827005W WO9932138A1 WO 1999032138 A1 WO1999032138 A1 WO 1999032138A1 US 9827005 W US9827005 W US 9827005W WO 9932138 A1 WO9932138 A1 WO 9932138A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cells
- cd40l
- cell
- binding
- ccr5
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2086—IL-13 to IL-16
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2000525129A JP2001526241A (en) | 1997-12-19 | 1998-12-18 | Methods for reducing susceptibility to HIV infection |
EP98964798A EP1059932A1 (en) | 1997-12-19 | 1998-12-18 | Method for reducing susceptibility to hiv infection |
CA002313805A CA2313805A1 (en) | 1997-12-19 | 1998-12-18 | Method for reducing susceptibility to hiv infection |
IL13673198A IL136731A0 (en) | 1997-12-19 | 1998-12-18 | Method for reducing susceptibility to hiv infection |
AU20041/99A AU2004199A (en) | 1997-12-19 | 1998-12-18 | Method for reducing susceptibility to hiv infection |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US6835597P | 1997-12-19 | 1997-12-19 | |
US60/068,355 | 1997-12-19 | ||
US9847498P | 1998-08-31 | 1998-08-31 | |
US60/098,474 | 1998-08-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1999032138A1 true WO1999032138A1 (en) | 1999-07-01 |
Family
ID=26748884
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1998/027005 WO1999032138A1 (en) | 1997-12-19 | 1998-12-18 | Method for reducing susceptibility to hiv infection |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1059932A1 (en) |
JP (1) | JP2001526241A (en) |
AU (1) | AU2004199A (en) |
CA (1) | CA2313805A1 (en) |
IL (1) | IL136731A0 (en) |
WO (1) | WO1999032138A1 (en) |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002036141A2 (en) * | 2000-11-02 | 2002-05-10 | Immunex Corporation | Method of enhancing lymphocyte-mediated immune responses |
US6511826B2 (en) | 1995-06-06 | 2003-01-28 | Human Genome Sciences, Inc. | Polynucleotides encoding human G-protein chemokine receptor (CCR5) HDGNR10 |
US6743594B1 (en) | 1995-06-06 | 2004-06-01 | Human Genome Sciences, Inc. | Methods of screening using human G-protein chemokine receptor HDGNR10 (CCR5) |
US7175838B2 (en) * | 2001-08-23 | 2007-02-13 | The United States Of America Represented By The Department Of Health And Human Services | Use of a promoter of T-cell expansion and an inducer of CD40 stimulation in the treatment or prevention of a pathologic state |
EP2583678A2 (en) | 2004-06-24 | 2013-04-24 | Novartis Vaccines and Diagnostics, Inc. | Small molecule immunopotentiators and assays for their detection |
KR101269548B1 (en) * | 2003-06-13 | 2013-06-21 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | Nucleic acid sequences encoding and compositions comprising IgE signal peptide and/or IL-15 and methods for using the same |
US8604178B2 (en) | 2006-09-18 | 2013-12-10 | The Board Of Trustees Of The University Of Arkansas | Compositions and methods of enhancing immune responses |
US8956618B2 (en) | 2010-01-21 | 2015-02-17 | The Texas A&M University System | Vaccine vectors and methods of enhancing immune responses |
US8956849B2 (en) | 2007-11-01 | 2015-02-17 | The Board Of Trustees Of The University Of Arkansas | Compositions and methods of enhancing immune responses to Eimeria |
US8961990B2 (en) | 2010-06-09 | 2015-02-24 | The Board Of Trustees Of The University Of Arkansas | Vaccine and methods to reduce campylobacter infection |
US9125854B2 (en) | 2007-10-30 | 2015-09-08 | The Board Of Trustees Of The University Of Arkansas | Compositions and methods of enhancing immune responses to flagellated bacterium |
US9603915B2 (en) | 2013-02-14 | 2017-03-28 | The Board of Trustees of the University of Akansas | Compositions and methods of enhancing immune responses to Eimeria or limiting Eimeria infection |
US10376571B2 (en) | 2013-03-15 | 2019-08-13 | The Board Of Trustees Of The University Of Arkansas | Compositions and methods of enhancing immune responses to enteric pathogens |
US10682398B2 (en) | 2016-05-03 | 2020-06-16 | The Texas A&M University System | Yeast vaccine vector including immunostimulatory and antigenic polypeptides and methods of using the same |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2006202318A1 (en) | 2005-06-02 | 2006-12-21 | Wing-Yee Chan | The preparation of multipotent stem cells and the use thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995014487A1 (en) * | 1993-11-24 | 1995-06-01 | The Australian National University | Treatment of viral disease with cd40l peptide |
WO1995017202A1 (en) * | 1993-12-23 | 1995-06-29 | Immunex Corporation | Method of preventing or treating disease characterized by neoplastic cells expressing cd40 |
WO1996026735A1 (en) * | 1995-03-01 | 1996-09-06 | Immunex Corporation | Method for stimulating an immune response |
-
1998
- 1998-12-18 JP JP2000525129A patent/JP2001526241A/en active Pending
- 1998-12-18 WO PCT/US1998/027005 patent/WO1999032138A1/en not_active Application Discontinuation
- 1998-12-18 IL IL13673198A patent/IL136731A0/en unknown
- 1998-12-18 AU AU20041/99A patent/AU2004199A/en not_active Abandoned
- 1998-12-18 EP EP98964798A patent/EP1059932A1/en not_active Withdrawn
- 1998-12-18 CA CA002313805A patent/CA2313805A1/en not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995014487A1 (en) * | 1993-11-24 | 1995-06-01 | The Australian National University | Treatment of viral disease with cd40l peptide |
WO1995017202A1 (en) * | 1993-12-23 | 1995-06-29 | Immunex Corporation | Method of preventing or treating disease characterized by neoplastic cells expressing cd40 |
US5674492A (en) * | 1993-12-23 | 1997-10-07 | Immunex Corporation | Method of preventing or treating disease characterized by neoplastic cells expressing CD40 |
WO1996026735A1 (en) * | 1995-03-01 | 1996-09-06 | Immunex Corporation | Method for stimulating an immune response |
Non-Patent Citations (2)
Title |
---|
DATABASE AIDSLINE June 1998 (1998-06-01), XP002102579 * |
DI MARZIO P. ET AL.: "GM-CSF or CD40L suppresses chemokine receptor expression and HIV-1 entry into human monocytes and macrophages", 5TH CONF. RETROVIR. OPPOR. INFECT., no. 37, 1998, U.S.A. * |
Cited By (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6511826B2 (en) | 1995-06-06 | 2003-01-28 | Human Genome Sciences, Inc. | Polynucleotides encoding human G-protein chemokine receptor (CCR5) HDGNR10 |
US6743594B1 (en) | 1995-06-06 | 2004-06-01 | Human Genome Sciences, Inc. | Methods of screening using human G-protein chemokine receptor HDGNR10 (CCR5) |
US6759519B2 (en) | 1995-06-06 | 2004-07-06 | Human Genome Sciences, Inc. | Antibodies to human G-protein chemokine receptor HDGNR10 (CCR5receptor) |
US6800729B2 (en) | 1995-06-06 | 2004-10-05 | Human Genome Sciences, Inc. | Human G-Protein chemokine receptor HDGNR10 (CCR5 receptor) |
WO2002036141A2 (en) * | 2000-11-02 | 2002-05-10 | Immunex Corporation | Method of enhancing lymphocyte-mediated immune responses |
WO2002036141A3 (en) * | 2000-11-02 | 2003-08-21 | Immunex Corp | Method of enhancing lymphocyte-mediated immune responses |
US7175838B2 (en) * | 2001-08-23 | 2007-02-13 | The United States Of America Represented By The Department Of Health And Human Services | Use of a promoter of T-cell expansion and an inducer of CD40 stimulation in the treatment or prevention of a pathologic state |
US7368106B2 (en) | 2001-08-23 | 2008-05-06 | The United States Of America As Represented By The Department Of Health And Human Services | Use of a promoter of T-cell expansion and an inducer of CD40 stimulation in the treatment or prevention of a pathologic state |
KR101269548B1 (en) * | 2003-06-13 | 2013-06-21 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | Nucleic acid sequences encoding and compositions comprising IgE signal peptide and/or IL-15 and methods for using the same |
EP2583678A2 (en) | 2004-06-24 | 2013-04-24 | Novartis Vaccines and Diagnostics, Inc. | Small molecule immunopotentiators and assays for their detection |
US8604178B2 (en) | 2006-09-18 | 2013-12-10 | The Board Of Trustees Of The University Of Arkansas | Compositions and methods of enhancing immune responses |
US9226957B2 (en) | 2006-09-18 | 2016-01-05 | The Texas A&M University System | Compositions and methods of enhancing immune responses |
US10004798B2 (en) | 2006-09-18 | 2018-06-26 | The Board Of Trustees Of The University Of Arkansas | Compositions and methods of enhancing immune responses |
US9125854B2 (en) | 2007-10-30 | 2015-09-08 | The Board Of Trustees Of The University Of Arkansas | Compositions and methods of enhancing immune responses to flagellated bacterium |
US8956849B2 (en) | 2007-11-01 | 2015-02-17 | The Board Of Trustees Of The University Of Arkansas | Compositions and methods of enhancing immune responses to Eimeria |
US10842858B2 (en) | 2007-11-01 | 2020-11-24 | The Board Of Trustees Of The University Of Arkansas | Compositions and methods of enhancing immune responses to Eimeria |
US10016493B2 (en) | 2007-11-01 | 2018-07-10 | The Board Of Trustees Of The University Of Arkansas | Compositions and methods of enhancing immune responses to Eimeria |
US8956618B2 (en) | 2010-01-21 | 2015-02-17 | The Texas A&M University System | Vaccine vectors and methods of enhancing immune responses |
US9913893B2 (en) | 2010-01-21 | 2018-03-13 | The Board Of Trustees Of The University Of Arkansas | Vaccine vectors and methods of enhancing immune responses |
US8961990B2 (en) | 2010-06-09 | 2015-02-24 | The Board Of Trustees Of The University Of Arkansas | Vaccine and methods to reduce campylobacter infection |
US10960068B2 (en) | 2010-06-09 | 2021-03-30 | The Board Of Trustees Of The University Of Arkansas | Vaccine and methods to reduce campylobacter infection |
US9603915B2 (en) | 2013-02-14 | 2017-03-28 | The Board of Trustees of the University of Akansas | Compositions and methods of enhancing immune responses to Eimeria or limiting Eimeria infection |
US10792351B2 (en) | 2013-02-14 | 2020-10-06 | The Board Of Trustees Of The University Of Arkansas | Compositions and methods of enhancing immune responses to Eimeria or limiting Eimeria infection |
US10328137B2 (en) | 2013-02-14 | 2019-06-25 | The Board Of Trustees Of The University Of Arkansas | Compositions and methods of enhancing immune responses to Eimeria or limiting Eimeria infection |
US9884099B2 (en) | 2013-02-14 | 2018-02-06 | The Board Of Trustees Of The University Of Arkansas | Compositions and methods of enhancing immune responses to Eimeria or limiting Eimeria infection |
US11364290B2 (en) | 2013-02-14 | 2022-06-21 | The Board Of Trustees Of The University Of Arkansas | Compositions and methods of enhancing immune responses to eimeria or limiting eimeria infection |
US11904005B2 (en) | 2013-02-14 | 2024-02-20 | The Board Of Trustees Of The University Of Arkansas | Compositions and methods of enhancing immune responses to Eimeria or limiting Eimeria infection |
US10376571B2 (en) | 2013-03-15 | 2019-08-13 | The Board Of Trustees Of The University Of Arkansas | Compositions and methods of enhancing immune responses to enteric pathogens |
US10716840B2 (en) | 2013-03-15 | 2020-07-21 | The Board Of Trustees Of The University Of Arkansas | Compositions and methods of enhancing immune responses to enteric pathogens |
US11013792B2 (en) | 2013-03-15 | 2021-05-25 | The Board Of Trustees Of The University Of Arkansas | Compositions and methods of enhancing immune responses to enteric pathogens |
US10682398B2 (en) | 2016-05-03 | 2020-06-16 | The Texas A&M University System | Yeast vaccine vector including immunostimulatory and antigenic polypeptides and methods of using the same |
US11382962B2 (en) | 2016-05-03 | 2022-07-12 | The Board Of Trustees Of The University Of Arkansas | Yeast vaccine vector including immunostimulatory and antigenic polypeptides and methods of using the same |
Also Published As
Publication number | Publication date |
---|---|
JP2001526241A (en) | 2001-12-18 |
IL136731A0 (en) | 2001-06-14 |
EP1059932A1 (en) | 2000-12-20 |
AU2004199A (en) | 1999-07-12 |
CA2313805A1 (en) | 1999-07-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Trinchieri et al. | Natural killer cell stimulatory factor (NKSF) or interleukin-12 is a key regulator of immune response and inflammation | |
US6905685B2 (en) | Methods of using antibodies to human receptor protein 4-1BB | |
Sim et al. | The IL-2 cytokine family in cancer immunotherapy | |
Trinchieri | Interleukin-12: a cytokine produced by antigen-presenting cells with immunoregulatory functions in the generation of T-helper cells type 1 and cytotoxic lymphocytes | |
Sinigaglia et al. | Regulation of the IL‐12/IL‐12R axis: a critical step in T‐helper cell differentiation and effector function | |
CA2087525C (en) | Adoptive immunotherapy with interleukin-7 | |
EP0751781B1 (en) | Use of monoclonal antibodies or soluble oligomeric ligands in the manufacture of a medicament for the prevention or treatment of neoplastic disorders | |
US8178308B2 (en) | Use of IL-27 agonists to increase interferon-gamma production | |
AU693526B2 (en) | Immuno-stimulatory monoclonal antibodies | |
EP1059932A1 (en) | Method for reducing susceptibility to hiv infection | |
Kornbluth | The emerging role of CD40 ligand in HIV infection | |
Levitt et al. | Production of granulocyte/macrophage-colony-stimulating factor by human natural killer cells. Modulation by the p75 subunit of the interleukin 2 receptor and by the CD2 receptor. | |
Nagumo et al. | Synergistic augmentative effect of interleukin‐10 and CD27/CD70 interactions on B‐cell immunoglobulin synthesis | |
Durandy et al. | Role of IL-6 in promoting growth of human EBV-induced B-cell tumors in severe combined immunodeficient mice. | |
US6074635A (en) | T cell activation | |
Yamane et al. | Effective stimulation for IL-12 p35 mRNA accumulation and bioactive IL-12 production of antigen-presenting cells interacted with Th cells | |
Bertagnolli et al. | IL-4-supported induction of cytolytic T lymphocytes requires IL-2 and IL-6 | |
Vieillard et al. | Transfer of human CD4+ T lymphocytes producing beta interferon in Hu-PBL-SCID mice controls human immunodeficiency virus infection | |
US6319493B1 (en) | Treatment of neoplastic disease with interleukin-10 | |
Huang et al. | Immunotherapy of multiple myeloma | |
WO2000009150A2 (en) | Cytokine and cytokine receptor, agonist, antagonist and/or antibody combination for therapeutic use | |
Zambello et al. | IL‐12 is involved in the activation of CD3+ granular lymphocytes in patients with lymphoproliferative disease of granular lymphocytes | |
VAN MEIR | Cytokine Expresssion in Brain Tumors: Its Role in Tumor Biology and Tumor-associated Immune Responses | |
Maeda et al. | Acquisition of HIV type 1 resistance by beta-chemokine-producing CD4+ T cells | |
Kalinski et al. | Interleukin-12 family (IL-12, 23, 12RA, and 27) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 136731 Country of ref document: IL |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AU BA BB BG BR CA CN CU CZ EE GE HR HU ID IL IS JP KP KR LC LK LR LT LV MG MK MN MX NO NZ PL RO SG SI SK SL TR TT UA US UZ VN YU |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 505009 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 20041/99 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 2313805 Country of ref document: CA Ref country code: CA Ref document number: 2313805 Kind code of ref document: A Format of ref document f/p: F |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2000 525129 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09596253 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1998964798 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1998964798 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1998964798 Country of ref document: EP |